Virologic and immunologic impact and durability of enfuvirtide-based antiretroviral therapy in HIV-infected treatment-experienced patients in a clinical setting

HIV Clinical Trials

Volumn 8, Issue 1, 2007, Pages 36-44

  Loutfy, Mona R ^a,b,e   Antoniou, T ^b,c   Shen, S ^a   Diong, C ^a   Vlaicu, M ^d   Halpenny, R ^b   Kovacs, C ^a,b   Fletcher, D ^a,b   Raboud, J M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b MAPLE LEAF MEDICAL CLINIC   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d McKesson Canada   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Enfuvirtide; HIV; Treatment experienced; Virologic durability; Virologic suppression

Indexed keywords

ABACAVIR; ENFUVIRTIDE; LOPINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; CANADA; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; HIV; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34047275409     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0801-36     Document Type: Article

References (21)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
2. Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ. 1999;160:659-665.
3. Struble K, Murray J, Cheng B, Gegeny T, Miller V, Gulick R. Antiretroviral therapies for treatment-experienced patients: current status and research challenges. AIDS. 2005;19:747-756.
4. Harris M, Montaner JS. Management of HIV-infected patients with multidrug-resistant virus. Curr HIV/AIDS Rep. 2004;1:116-121.
5. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2006. Available at: http://AIDSinfo.nih.gov.
6. Oldfield V, Keating GM, Plosker G. Enfuvirtide: a review of its use in the management of HIV infection. Drugs. 2005;65(8):1139-1160.
7. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA. 1994;91:9770-9774.
8. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med. 1998;4:1302-1307.
9. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175-2185.
10. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186-2195.
11. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr. 2005;40:404-412.
12. Trottier B, Walmsley S, Reynes J, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr. 2005;40:413-421.
13. Raffi F, Katlama C, Saag M, et al. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. Clin Infect Dis. 2006;42:870-877.
14. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc. 1979;74:829-836.
15. Arasteh K, Lazzarin A, Clotet B, et al. TORO: 96 week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen. Presented at: XV International AIDS Conference; July 11-16, 2004; Bangkok. Abstract MoOrB1058.
16. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368:466-475.
17. Katlama C, Carvalho MT, Cooper D, et al. TMC114/r out-performs investigator-selected PI(s) in 3-class-experienced patients: week 24 primary efficacy analysis of POWER 1 (TMC114-C213). Presented at: Third IAS Conference on HIV Pathogenesis and Treatment; July 24-27, 2005; Rio De Janeiro. Poster WeOaLBO102.
18. Wilkin T, Haubrich R, Steinhart CR, et al. TMC114/r superior to standard of care in 3-class-experienced patients: 24-wks primary analysis of the POWER 2 study (C202). Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC. Abstract H-413.
19. Harris M, Joy R, Larsen G, et al. Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector). AIDS. 2006;20:719-723.
20. Bienvenu B, Krivine A, Rollot F, et al. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice. J Med Virol. 2006;78:1312-1317.
21. Xu L, Hue S, Taylor S, et al. Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naïve and -experienced patients. AIDS. 2002;16:1684-1686.